alpha-MSH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-18. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
A substance can often be classified as an acid or a base. There are several different theories which explain acid–base behavior. The simplest is Arrhenius theory, which states that an acid is a substance that produces hydronium ions when it is dissolved in water, and a base is one that produces hydroxide ions when dissolved in water. According to Brønsted–Lowry acid–base theory, acids are substances that donate a positive hydrogen ion to another substance in a chemical reaction; by extension, a base is the substance which receives that hydrogen ion. A third common theory is Lewis acid–base theory, which is based on the formation of new chemical bonds. Lewis theory explains that an acid is a substance which is capable of accepting a pair of electrons from another substance during the process of bond formation, while a base is a substance which can provide a pair of electrons to form a new bond. There are several other ways in which a substance may be classified as an acid or a base, as is evident in the history of this concept. Acid strength is commonly measured by two methods. One measurement, based on the Arrhenius definition of acidity, is pH, which is a measurement of the hydronium ion concentration in a solution, as expressed on a negative logarithmic scale. Thus, solutions that have a low pH have a high hydronium ion concentration and can be said to be more acidic.
Starting from the 1990s, major discoveries of exceptionally preserved fossils in deposits known as conservation Lagerstätten contributed to research on dinosaur soft tissues. Chiefly among these were the rocks that produced the Jehol (Early Cretaceous) and Yanliao (Mid-to-Late Jurassic) biotas of northeastern China, from which hundreds of dinosaur specimens bearing impressions of feather-like structures (both closely related to birds and otherwise, see § Origin of birds) have been described by Xing Xu and colleagues. In living reptiles and mammals, pigment-storing cellular structures known as melanosomes are partially responsible for producing colouration. Both chemical traces of melanin and characteristically shaped melanosomes have been reported from feathers and scales of Jehol and Yanliao dinosaurs, including both theropods and ornithischians. This has enabled multiple full-body reconstructions of dinosaur colouration, such as for Sinosauropteryx and Psittacosaurus by Jakob Vinther and colleagues, and similar techniques have also been extended to dinosaur fossils from other localities. (However, some researchers have also suggested that fossilized melanosomes represent bacterial remains.) Stomach contents in some Jehol and Yanliao dinosaurs closely related to birds have also provided indirect indications of diet and digestive system anatomy (e.g., crops). More concrete evidence of internal anatomy has been reported in Scipionyx from the Pietraroja Plattenkalk of Italy. It preserves portions of the intestines, colon, liver, muscles, and windpipe.
==== Arrest and death ==== In 1977, Biko broke his banning order by travelling to Cape Town, hoping to meet Unity Movement leader Neville Alexander and deal with growing dissent in the Western Cape branch of the BCM, which was dominated by Marxists like Johnny Issel. Biko drove to the city with his friend Peter Jones on 17 August, but Alexander refused to meet with Biko, fearing that he was being monitored by the police. Biko and Jones drove back toward King William's Town, but on 18 August they were stopped at a police roadblock near Grahamstown. Biko was arrested for having violated the order restricting him to King William's Town. Unsubstantiated claims have been made that the security services were aware of Biko's trip to Cape Town and that the road block had been erected to catch him. Jones was also arrested at the roadblock; he was subsequently held without trial for 533 days, during which time he was interrogated on numerous occasions. The security services took Biko to the Walmer police station in Port Elizabeth, where he was held naked in a cell with his legs in shackles. On 6 September, he was transferred from Walmer to room 619 of the security police headquarters in the Sanlam Building in central Port Elizabeth, where he was interrogated for 22 hours, handcuffed and in shackles, and chained to a grille. Exactly what happened has never been ascertained, but during the interrogation he was severely beaten by at least one of the ten security police officers. He suffered three brain lesions that resulted in a massive brain haemorrhage on 6 September.
=== Subunit expression and synthesis === Upon identifying the target subunit and its encoding gene, the gene will be isolated and transferred to a second, non-pathogenic organism, and cultured for mass production. The process is also known as heterologous expression. A suitable expression system is selected based on the requirement of post-translational modifications, costs, ease of product extraction and production efficiency. Commonly used systems for both licensed and developing recombinant subunit vaccines include bacteria, yeast, mammalian cells, insect cells.
== Technology life cycle == Silica monoliths have only been commercially available since 2001, when Merck began their Chromolith campaign. The Chromolith technology was licensed from Soga and Nakanishi's group at Kyoto University. The new product won the PittCon Editors’ Gold Award for Best New Product, as well as an R&D 100 Award, both in 2001. Individual monolith columns have a life cycle that generally exceeds that of its particulate competitors. When selecting an HPLC column supplier, column lifetime was second only to column-to-column reproducibility in importance to the purchaser. Chromolith columns, for example, have demonstrated reproducibility of 3,300 sample injections and 50,000 column volumes of mobile phase. Also important to the life cycle of the monolith is its increased mechanical robustness; polymeric monoliths are able to withstand pH ranges from 1 to 14, can endure elevated temperatures, and do not need to be handled delicately. “Monoliths are still teenagers,” affirms Frantisec Svec, a leader in the field of novel stationary phases for LC.
Sources: en.wikipedia.org
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 4 September The Tin Snail, about the Citroën 2CV; the 2CV was first introduced in October 1948; André Citroën saw himself as a French Henry Ford, and met American automotive industrialists in October 1931, including Henry Ford at the newly opened Ford Engineering Laboratory; the industrial historian Patrick Fridenson; Citroën lit up the Eiffel Tower in Citroën regalia, for publicity; but although André Citroën followed and admired Henry Ford, Citroën were innovative themselves, on 18 April 1934 the company launched the world's first mass-produced front-wheel drive car, the Citroën Traction Avant, when the company was narrowly avoiding bankruptcy; André Citroën died in 1935 and his company, being heavily in debt, was taken over by Édouard Michelin (brother of André Michelin); Fiat introduced its similar Fiat 500 in 1935, designed by Dante Giacosa; Ferdinand Porsche designed a new mass-produced car with rear air-cooled horizontally-opposed four-cylinder engine; France did not have such a car to Germany, so Citroën developed the Toute Petite Voiture (TPV), a proposal of Pierre Michelin - he brought in André Lefèbvre, who had designed the front-wheel-drive system of the Traction Avant and was a former aircraft engineer of Voisin, and led by Pierre-Jules Boulanger; Lefèbvre came from the aviation industry, and to save weight, made the car out of aluminium; the car had a torsion bar suspension, with eight torsion bars; Flaminio Bertoni, an Italian, was head of exterior design at Citroën, from 1932 to 1964; Carl Olsen, head of Citroën exterior design from 1982 to 1987; Alex Moulton, the Cambridge-educated mechanical engineer, who designed the suspension for the innovative Mini, in the late 1950s; Lucien Gerard, from Talbot, and Walter Becchia, who designed the two-cylinder water-cooled horizontally opposed engine. Narrated by Peter Jones, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 11 September Deep Trouble, about the North Sea oil industry; the beginning of 1986 saw peak production of North Sea oil; finding new oil reserves would be from deeper oil fields, that cost more money to extract; at the same time the oil price plummeted, with over 15,000 job losses in the British oil industry by the end of 1986; Vickers Ltd entered the oil exploration industry; submersible craft were helping exploration of oil, with remotely operated craft becoming important. Narrated by Martin Jarvis, produced by Patrick Uden, directed by Paul Fabricius, made by Uden Associates 18 September What They Don't Tell You When They Sell You a Computer, about professionalism in the computer hardware industry; Eddy Shah from the Today newspaper, and their new unreliable computer system; Brian Wilson of First Computer believed that the computer hardware retailing industry were largely unprofessional unscrupulous cowboys; the National Computing Centre (NCC) was set up by the government in 1966, to provide advice; BP opened its own Microshop, to circumvent the cowboys, and assist with technical jargon, and connecting devices; due to warp-drive technical obsolescence in the 1980s, yesterday's computers rapidly lost all total value; Iain Callaghan, operations director of John Menzies newspaper distribution business, and how computer databases could process newsagents' daily orders much quicker and reliably; Geoff Dalby, head of data at Woolwich Equitable Building Society, which had called off a merger with the Nationwide Building Society, as their computer systems would not work together; greater computer automation of the personal finance industry could lead to much less day-to-day contact with individual customers; David Bailey of Phillips & Drew. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 25 September Precisely in Profit, about manufacturing to exact margins. Produced by Glyn Jones, directed by Eben Wilson, made by Quanta 2 October Now Eat This, about snack foods. Produced by Edward Poulter, directed by Mike Tomlinson, made by London Scientific Films 9 October Growing up with Rockets, a personal, and underreported, view of early elementary rocketry from 1950, starting with captured German V-2 rockets; the former 1970 class of Cocoa Beach High School; failed launches would land in the Banana River; NASA was formed in July 1958, in a coherent response to the Russian launches in 1957; the President visits Cocoa Beach to celebrate the US getting a man to orbit the Earth in February 1962; the nearby Patrick Air Force Base; Syncom 3 was launched on 19 August 1964, the world's first geostationary communication satellite, on a Delta rocket; the minutes leading up to the first launch of STS-1 in April 1981. Directed and a first hand account of Nancy Yasecko, produced by Patrick Uden, made by Uden Associates 16 October Shock Trauma, about the Baltimore Shock Trauma Center (R Adams Cowley Shock Trauma Center). A Canadian production, produced by Patrick Uden, made by National Film Board of Canada and Uden Associates 23 October Drink Drive and Murder; it featured two court cases in the US, where a 33 year old killed a couple in their 20s, and a 17 year old who killed a couple of teenagers, and a Californian drink-drive reform centre; in some US states, if you kill when drunk, the charge is murder. A Canadian production, made by Uden Associates and the National Film Board of Canada 30 October The New Magicians, about film special effects; Gertie the Dinosaur in 1914 and The Sinking of the Lusitania in 1918; the King Kong (1933 film); the 1950s and 1960s saw modest increases in special effects, notably Forbidden Planet in 1956, until 2001: A Space Odyssey was important in 1968; another important film was Star Wars (film) in 1977, along with Close Encounters of the Third Kind, Tron in 1982 and The Last Starfighter in 1984. A Canadian production, produced by Ken McKay, made by TV Ontario 6 November Pioneers of the Future, about the development of microchips, such as Steve Dorsey, who invented the word processor. A Canadian production, produced by Ken McKay, made by Uden Associates and TV Ontario 13 November Skyscraper, about Old Madison Square Gardens and skyscrapers in Chicago and New York; Arthur Nusbaum; architect Stanley Tigerman; the tallest masonry-only building was 16 storeys high; the Great Chicago Fire in October 1871, which allowed different, and stronger, structures of building to be built instead; the 1902 Flatiron Building; architect Jack Hartray; mechanical engineer George Strakosch; the 1908 600-feet Singer Building; the 1912 800-feet Woolworth Building; the 1915 Equitable Building (Manhattan); the 1930 900-feet Chrysler Building; the 1931 1250-feet Empire State Building; mechanical engineer David Stillman; structural engineer Charles Thornton; architect Robert Sobel; structural engineer Leslie E. Robertson; civil engineer Alan Garnett Davenport of the University of Western Ontario; architect Bruce Graham; architect Harry Weese; architect Moshe Safdie. Narrated by William Woollard, produced by Nicola Glucksmann, directed by Karl Sabbagh, made by InCA
== Signaling pathways == Induction of FPR triggers multiple changes in eukaryotic cells including rearrangement of the cytoskeleton which in turn facilitates cell migration and the synthesis of chemokines. Important FPR regulated pathways include:
=== Blood–brain barrier permeability === Beta blockers vary in their lipophilicity (fat solubility) and in turn in their ability to cross the blood–brain barrier and exert effects in the central nervous system. Beta blockers with greater blood–brain barrier permeability can have both neuropsychiatric therapeutic benefits and side effects, as well as adverse cognitive effects. Central nervous system-related side effects and risks of beta blockers may include fatigue, depression, sleep disorders (namely insomnia) and nightmares, visual hallucinations, delirium, psychosis, Parkinson's disease, and falling. Conversely, central nervous system-related benefits of beta blockers may include prevention and treatment of migraine, essential tremor, akathisia, anxiety, post-traumatic stress disorder, aggression, and obsessive–compulsive disorder. Most beta blockers are lipophilic and can cross into the brain, but there are a number of exceptions. Highly lipophilic beta blockers include penbutolol, pindolol, propranolol, and timolol, moderately lipophilic beta blockers include acebutolol, betaxolol, bisoprolol, carvedilol, metoprolol, and nebivolol, and low lipophilicity or hydrophilic beta blockers include atenolol, carteolol, esmolol, labetalol, nadolol, and sotalol. It is thought that highly lipophilic beta blockers are able to readily cross into the brain, moderately lipophilic beta blockers are able to cross to a lesser degree, and low lipophilicity or hydrophilic beta blockers are minimally able to cross.
== History == The efficacy of ceftolozane/tazobactam to treat complicated intra-abdominal infections (cIAI) in combination with metronidazole was established in a clinical trial with a total of 979 adults. Participants were randomly assigned to receive ceftolozane/tazobactam plus metronidazole or meropenem. Results showed ceftolozane/tazobactam plus metronidazole was effective for the treatment of cIAI. The efficacy of ceftolozane/tazobactam to treat complicated urinary tract infections (cUTI) was established in a clinical trial where 1,068 adults were randomly assigned to receive ceftolozane/tazobactam or levofloxacin. Ceftolozane/tazobactam demonstrated it was effective in treating cUTI. Ceftolozane/tazobactam was shown to be at least as effective as other antibiotics in curing infections in three main studies. One study involved 1,083 participants who mostly had kidney infection or in some cases a complicated urinary-tract infection. Ceftolozane/tazobactam successfully treated the infection in about 85% of the cases where it was given (288 of 340), compared with 75% (266 of 353) of those given another antibiotic called levofloxacin. The second study involved 993 participants with complicated intra-abdominal infections. Ceftolozane/tazobactam was compared with another antibiotic, meropenem. Both medicines cured 94% of participants (353 out of 375 given ceftolozane/tazobactam and 375 out of 399 given meropenem). The third study involved 726 participants who were using a ventilator and who had either hospital-acquired pneumonia or ventilator-associated pneumonia.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.